-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $30

Benzinga·11/19/2025 12:39:01
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $40 to $30.